^
13d
CHIRON: ATL001 in Patients with Advanced Unresectable or Metastatic NSCLC (clinicaltrials.gov)
P1/2, N=27, Terminated, Achilles Therapeutics UK Limited | N=50 --> 27 | Trial completion date: Jul 2027 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Sep 2024; Sponsor decision
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
Keytruda (pembrolizumab) • ATL 001
13d
THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov)
P1/2, N=13, Terminated, Achilles Therapeutics UK Limited | N=40 --> 13 | Trial completion date: Jul 2027 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Sep 2024; Sponsor decision
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
Opdivo (nivolumab) • ATL 001
11ms
THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov)
P1/2, N=40, Recruiting, Achilles Therapeutics UK Limited | Trial completion date: Dec 2027 --> Jul 2027
Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
Opdivo (nivolumab) • ATL 001
12ms
Long-Term Follow-Up Study of Patients Receiving ATL001 (clinicaltrials.gov)
P2, N=1, Terminated, Achilles Therapeutics UK Limited | N=90 --> 1 | Trial completion date: Jul 2028 --> Oct 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Jul 2028 --> Oct 2023; The long-term follow-up of patients is being migrated to the original (parent) study protocols (Trial ID: ATX-NS-001 / NCT: NCT04032847;Trial ID: ATX-ME-001 / NCT: NCT03997474). Consequently, the ATX-LTFU-001 study is being terminated by the Sponsor.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
ATL 001
almost2years
THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov)
P1/2, N=40, Recruiting, Achilles Therapeutics UK Limited | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Jul 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
Opdivo (nivolumab) • ATL 001